Cohort Study for Atrial Fibrillation Risk Stratification
AFHRI
An Epidemiologic, Prospective, Single Center Cohort Study for the Improvement of Atrial Fibrillation Risk Stratification in High Risk Individuals
1 other identifier
observational
3,000
1 country
1
Brief Summary
AFHRI is planned as a prospective, single-center cohort study in patients at high risk of AF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 29, 2022
CompletedFirst Posted
Study publicly available on registry
July 5, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
May 13, 2024
May 1, 2024
13.6 years
June 29, 2022
May 10, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Incident atrial fibrillation
12-lead Electrocardiogram (ECG) tracing, diagnosis of AF will be made if at least two cardiologists verify the rhythm abnormality using clinic visit, outside physician or hospital records, or ambulatory ECG reports.
up to 4 years
Secondary Outcomes (3)
Myocardial infarction
up to 4 years
Cardiovascular death
up to 4 years
Heart failure
up to 4 years
Eligibility Criteria
Outpatient cardiology sample at risk for AF. Recruitment in a single center design, at the Department of Cardiology, University Medical Center Hamburg-Eppendorf.
You may qualify if:
- Age 18 to 85 years;
- Personally signed informed consent
You may not qualify if:
- Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation;
- Physical or psychological incapability to cooperate in the investigations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Cardiology, University Medical Center Hamburg-Eppendorf
Hamburg, 20246, Germany
Related Publications (1)
Assum I, Krause J, Scheinhardt MO, Muller C, Hammer E, Borschel CS, Volker U, Conradi L, Geelhoed B, Zeller T, Schnabel RB, Heinig M. Tissue-specific multi-omics analysis of atrial fibrillation. Nat Commun. 2022 Jan 21;13(1):441. doi: 10.1038/s41467-022-27953-1.
PMID: 35064145RESULT
Related Links
Biospecimen
sophisticated biobank including DNA, RNA, cells, and serum/plasma for comprehensive genetic, gene expression and proteomic studies
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Renate B Schnabel, Prof.
Department of Cardiology, University Medical Center Hamburg-Eppendorf
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 29, 2022
First Posted
July 5, 2022
Study Start
June 1, 2013
Primary Completion (Estimated)
January 1, 2027
Study Completion (Estimated)
January 1, 2030
Last Updated
May 13, 2024
Record last verified: 2024-05